Supernus Pharmaceuticals, Inc.
SUPN
$50.35
$0.440.88%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 211.57M | 192.10M | 165.45M | 149.82M | 174.16M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 211.57M | 192.10M | 165.45M | 149.82M | 174.16M |
| Cost of Revenue | -55.40M | 48.33M | 16.83M | 15.76M | -54.05M |
| Gross Profit | 266.97M | 143.77M | 148.63M | 134.06M | 228.21M |
| SG&A Expenses | 197.36M | 110.97M | 94.55M | 94.34M | 81.61M |
| Depreciation & Amortization | 24.53M | 24.33M | 20.82M | 19.79M | 18.24M |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 272.72M | 183.63M | 154.31M | 156.82M | 154.60M |
| Operating Income | -61.15M | 8.48M | 11.14M | -7.00M | 19.56M |
| Income Before Tax | -1.91M | -57.95M | 16.67M | -5.83M | 26.38M |
| Income Tax Expenses | 2.19M | -12.84M | -5.83M | 6.00M | 11.05M |
| Earnings from Continuing Operations | -4.11M | -45.12M | 22.50M | -11.83M | 15.33M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -4.11M | -45.12M | 22.50M | -11.83M | 15.33M |
| EBIT | -61.15M | 8.48M | 11.14M | -7.00M | 19.56M |
| EBITDA | -36.14M | 33.28M | 32.50M | 13.39M | 38.41M |
| EPS Basic | -0.07 | -0.80 | 0.40 | -0.21 | 0.28 |
| Normalized Basic EPS | -0.64 | 0.12 | 0.17 | -0.03 | 0.28 |
| EPS Diluted | -0.07 | -0.80 | 0.40 | -0.21 | 0.27 |
| Normalized Diluted EPS | -0.64 | 0.12 | 0.17 | -0.03 | 0.27 |
| Average Basic Shares Outstanding | 57.34M | 56.55M | 56.02M | 55.86M | 55.47M |
| Average Diluted Shares Outstanding | 57.34M | 56.55M | 56.64M | 55.86M | 56.46M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |